Mutations in KRAS are the earliest events in pancreatic cancer initiation, and it is reported that expression of GSK-3b rises during progression of pancreatic cancer from preneoplastic lesions, suggesting a possible role for this oncogene in the observed overexpression (Ougolkov et al., 2006). This evidence concerns the gene KRAS and familial pancreatic carcinoma.